[Endometrial ablation with thermal balloon, experience in a private hospital]. / Ablación endometrial con balón térmico, experiencia en un hospital privado.

BACKGROUND: Traditionally, the treatment for menorrhagia includes pharmacological therapies (hormones and uterotonics) or surgical (dilatation/curettage and hysterectomy). Recently the FDA approved a non-invasive therapeutic option, known as endometrial ablation. Which it consists in a thermal balloon delivers (ThermaChoice y Thermablate EAS) which energy destroys the uterine lining, thus reducing the bleeding and even producing amenorrhea. And could offer other benefits such as reduction of the surgical time, and therefore: anesthesia time, postoperative complications and costs. Highlighting a greater patient satisfaction. OBJECTIVE: Describe the demographic characteristics, outcomes and patient satisfaction, which were treated with endometrial ablation for menorrhagia. MATERIAL AND METHODS: A descriptive, observational and retrospective study. During a period of 11 years (March 2012 to December 2013), in a private hospital, that includes 124 patients with menorrhagia, which were treated with endometrial ablation: 53 (43%) ThermaChoice y 71 (57%) Thermablate EAS. We used T Student and Fisher method to study the results. RESULTS: The 124 patients (100%) achieve all the criteria's of endometrial ablation according ACOG (American College of Obstetricians and Gynecologists) were candidates for. The mean age of our patients were 38 years old, who didn't respond to pharmacologic treatment had a definitive contraception. Among these women, 119 (96%) had a reduction in bleeding en the first 12 months, 25 (31%) presented with amenorrhea and 1 (<1%) required a surgical approach. Overall, 119 patients (96%) were satisfied with their results. CONCLUSIONS: Endometrial ablation is an approved FDA treatment for menorrhagia, which is safe, accessible and effective. With an easy implementation and low rate of complications.

[Peripartum cardiomyopathy: a case report]. / Miocardiopatía periparto: reporte de un caso.

Background: Peripartum cardiomyopathy also known as cardiomyopathy associated with pregnancy, is rarely a cause of heart failure, it affects pregnant or puerperal women in the first 5 months. Although the first case reported was in 1849, it was recognized until 1930. In 2010 the European Society of Cardiology Working Group on peripartum cardiomyopathy, defined this pathology as an idiopathic cardiomyopathy that affects pregnant women between the third trimester and five months after delivery. Characterized by a left ventricular failure with an ejection fraction of ≤45% and an end-diastolic dimension ≥2.7 cm/m2 , in absence of an identifiable cause of heart failure. Case report: We report a case of a 39-year-old patient, diagnosed with a peripartum cardiomyopathy in the early puerperium, characterized by hypertension, tachycardia, dyspnea and oxygen desaturation. The transesophageal echocardiogram reported heart failure, a hypokinetic left ventricle and a ventricular failure with an ejection fraction <40%. We could not identify an other cause to justify heart failure. Multidisciplinary management was administered successfully. Conclusion: The importance of this article relies in the fact that eripartum cardiomyopathy has a high morbidity and mortality. The impact of this pathology is unknow in our country. Here we establish and discuss the multidisciplinary management held in our hospital with this specific patient in order to improve the prognosis on future occasions.